1. Assessing user fees under the Biosimilar User Fee Amendments of 2017 Publication: Silver Spring, MD : Center for Drug Evaluation and Research, January 2020 Subject(s): Biosimilar Pharmaceuticals -- economicsDrug Development -- economicsUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
